The LAB10x name was chosen by the partners collectively to signify how critical data-driven healthcare can be accelerated from concept to innovation ten times faster, as the result of the cumulative experience of the LAB10x partners involved and by applying an agile development methodology within a regulated framework. Because in healthcare, time is of the essence.
LAB10x is governed by the Joint Steering Committee, which comprises representatives from Sensyne Health, the University of Oxford, OUI, Evotec and OSI.
The Joint Steering Committee decides on which projects are funded.
There is no fixed limit to the number of awards to be made per annum.
LAB10x is not a distinct legal entity – it is a partnership.
Arising IP will be treated according to Oxford University statutes.Sensyne Health and Evotec, together with OSI, will have the right to co-invest in seed financing rounds. Where company creation is not the chosen commercial path, Sensyne will have the right to acquire a licence to IP generated by the selected projects.
Applicants should work with OUI to identify their relevant background intellectual property controlled by Oxford that would form part of a package of IP to be licensed to a spinout, based on results of a LAB10x funded project. It is expected that, subject to any 3rd party rights, Background IP (i.e. IP existing before LAB10x projects start) will be included in any such package, as far is it is needed to enable exploitation of Arising IP from the project.
LAB10x has been established to fuel the creation of new spinout companies from the University of Oxford, and spinout formation will be the preferred route to commercialise the outputs from funded projects. Spinouts based on the results of LAB10x awards will be established based on an equity and IP licence framework agreed by the partners. For more information, please contact Oxford University Innovation.
Where a new spinout company is formed based on LAB10x results, academics will – as is currently the case for Oxford spinouts – benefit from founding equity and/or a share of revenues generated under the IP licence.
The researchers will be free to work with OUI to establish alternative routes to commercialise LAB10x results.
Academics and clinicians from the University of Oxford and Oxford University Hospitals NHS Foundation Trust with an idea for a digital health technology that has the potential to revolutionise;
The EIR is embedded in the University and is intended to be a valuable resource for academics wishing to consult an entrepreneurial expert in digital health, on how best to shape and plan projects. The remit of the EIR is to support the development and validation of value propositions and business models. The EIR works in a highly integrated fashion with OUI, other University functions, and the other LAB10x stakeholders, to ensure the smooth operation of the partnership.
Applicants benefit from financial support for funded projects and from the combined technical expertise and physical resources of the LAB10x partners in the translation of research into possible real-world digital health innovations. Applicants will have access to engineering support and mentoring for regulated software development and data analysis as well as ‘How-to’ workshops. LAB10x can also help with introductions to industry specialists, suppliers and partners.
LAB10x will be an important catalyst for clinical AI and digital health projects from Oxford, but academics are under no obligation to use it for their specific needs. We encourage interested academics to first discuss their specific project with OUI in order to determine how well suited LAB10x may be versus other sources of funding.
This does not necessarily preclude an application to LAB10x, but applicants should work with OUI to ensure that an application does not conflict with any 3rd party rights.
Prior receipt of proof of concept funding from Oxford’s internal funds or from external sources does not necessarily preclude an application to LAB10x, but such awards should be disclosed in an application and discussed with OUI to ensure eligibility.
The LAB10x partners, including the Expert in Residence, are under a duty of confidentiality regarding information disclosed to them in the course of the partnership. However, information should not be disclosed to LAB10x which is subject to a duty of confidentiality to a 3rd party; for example, where research results have been generated from a project with a commercial sponsor. If in doubt, researchers should first check with Research Services and Oxford University Innovation Ltd.
It is expected that where possible the projects will be undertaken at the BioEscalator on the Old Road Campus; or otherwise, at Sensyne Health’s offices on the Oxford Science Park.
The LAB10x Joint Steering Committee and Expert in Residence (EIR) will monitor progress and make go/no-go decisions should awards be tranched.
This will vary depending on the nature of the funded project, but even where any of the development work is being undertaken outside of the University, the applicant will play an active role in guiding and managing the project.
LAB10x is unable to consider basic research projects and non-digital health projects that aim to develop a specific pharmaceutical therapeutic asset. If in doubt, please contact Oxford University Innovation Ltd (OUI). It is not intended to provide funding for academics’ salaries.
LAB10x is made possible through a collaboration between Sensyne Health plc, Evotec SE, the University of Oxford, Oxford University Innovation Ltd and Oxford Sciences Innovation plc.
©LAB10x 2022. All Rights Reserved.